Cormorant Asset Management, an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles, and OneVentures, a venture capital firm, investing in truly innovative technology and healthcare companies, led a $18m Series B round in BiVACOR, a designer and manufacturer of centrifugal heart pumps. “We are extremely grateful for the ongoing support from our core investors. This additional commitment further validates our technology and the need for improved options to treat end-stage biventricular heart failure. With this financing, we will be able to double the size of our organization and add key positions from the c-suite to research and development. We are well positioned to advance our preclinical activities and aim to conduct our First in Human early feasibility study planned for the end of the year,” Thomas Vassiliades, BiVACOR CEO.